Comparative efficacy of tulathromycin, tilmicosin, and florfenicol in the treatment of bovine respiratory disease in stocker cattle.
The therapeutic efficacy and field safety of tulathromycin were evaluated in stocker calves with undifferentiated bovine respiratory disease (BRD) in three field studies conducted over two consecutive grazing seasons in Nebraska. Eight hundred calves exhibiting clinical signs of BRD and with rectal temperatures of 104 degrees F or higher were treated with tulathromycin (n = 340), florfenicol (n = 240), or tilmicosin (n = 220) and evaluated for approximately 60 days. Florfenicol and tilmicosin were administered as single SC injections according to labeled dosage. Tulathromycin was administered as a single SC injection of 2.5 mg/kg. In all three studies, the cure rate of calves 60 days after treatment with tulathromycin was significantly higher (P < or = .05) than that of calves treated with florfenicol or tilmicosin. Suspected adverse reactions were not reported for any of the study drugs. Tulathromycin proved to be significantly more effective than either florfenicol or tilmicosin in the treatment of BRD in stocker calves.
Nutsch
Robert G
RG
Pfizer Animal Health, Veterinary Medicine Research and Development, Kalamazoo, MI 49001, USA.
Skogerboe
Terry L
TL
Rooney
Kathleen A
KA
Weigel
Daniel J
DJ
Gajewski
Kimberly
K
Lechtenberg
Kelly F
KF
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002417:Cattle; D004187:Disaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous / Q000662:veterinary; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D012766:Pasteurellosis, Pneumonic / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012720:Severity of Illness Index; D013839:Thiamphenicol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States; D015430:Weight Gain
D000900:Anti-Bacterial Agents; D004187:Disaccharides; D006571:Heterocyclic Compounds; D018942:Macrolides; C035534:florfenicol; D013839:Thiamphenicol; C485204:tulathromycin; C052319:tilmicosin; D015645:Tylosin